Politics, Policy & Law

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">IPR battles</h1><h2 class="title-bottom webtitle">Who&apos;s winning and who&apos;s losing at IPR so far</h2><div class="byline">Steve Usdin, Washington Editor</div><div class="date"></div></div></div></div>

autoimmune

Dermatology

Neurology

IPR battles

So far, inter partes review hasn't been a drug patent killer, but BIO and PhRMA say it is a threat that must be slain.

Who's winning and who's losing at IPR so far

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>